METTL14 inhibits the migration and invasion of renal cancer cells by downregulating purinergic receptor P2X 6 (P2RX6) protein translation and ATP-P2RX6-Ca2+-p-ERK1/2-MMP9 signalling in renal cell carcinomas (Wang et al., 2019b). Here, P2RX6 is linked to renal carcinoma.